Search - tctmd.com

Displaying 941 - 960 of 1090

Sort: Relevancy | Date

Presentation TCT 2016

Percutaneous Suture Based PFO Closure with the NobleStitch EL Device: Initial Multicenter Clinical Experience

Presenter: Ted Feldman, David Hildick-Smith, Michael J. Mullen

November 01, 2016

Presentation TCT 2016

Prospective Single Center FIH Clinical Trial to Evaluate the Safety and Effectiveness of a Septal Occluder with Bioresorbable Framework in Patients with Clinically Significant ASD or PFO

Presenter: Ted Feldman, David Hildick-Smith, Kolja Sievert

November 01, 2016

Presentation TCT 2016

Trial #9 - The Essentials ofIN.PACT SFA: 3-year Outcomes of a Paclitaxel-Coated Balloon for Femoropopliteal Lesions

Presenter: William A. Gray, Stephan Windecker, John R. Laird Jr.

October 31, 2016

Presentation TCT 2016

ACT I Critique: Pro and Con

Presenter: William A. Gray, Stephan Windecker, Klaus D. Mathias

October 31, 2016

Presentation TCT 2016

Trial #8 - The Essentials ofThe ACT I Trial: Carotid Stenting vs Surgery In Asymptomatic Patients

Presenter: William A. Gray, Stephan Windecker, Kenneth Rosenfield

October 31, 2016

Presentation TCT 2016

CTSN Severe MR 2-Year Critique: Pro and Con

Presenter: William A. Gray, Stephan Windecker, Patrick M. McCarthy

October 31, 2016

Presentation TCT 2016

Trial #7 - The Essentials ofCTSN SMR Trial - Two-Year Outcomes Following Mitral Valve Repair or Replacement for Severe Ischemic Mitral Regurgitation

Presenter: William A. Gray, Stephan Windecker, Michael Argenziano

October 31, 2016

Presentation TCT 2016

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Presenter: William A. Gray, Stephan Windecker

October 31, 2016

Presentation TCT 2016

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

Presenter: William A. Gray, Stephan Windecker, Vinod H. Thourani

October 31, 2016

Presentation TCT 2016

Case Resolution: How Did We Treat this Patient?

Presenter: Nick Curzen, Michael Mahmoudi

October 31, 2016

Presentation TCT 2016

TAVR Restenosis: Review of the Literature

Presenter: Nick Curzen

October 31, 2016

Presentation TCT 2016

Case Introduction: An 87 Year Old Woman With Recurrent Dyspnea 7 Years After TAVR

Presenter: Nick Curzen, Michael Mahmoudi

October 31, 2016

Presentation TCT 2016

TAVR for Intermediate-Risk and Low-Risk Patients: Review of the Literature

Presenter: Niall T. Mulvihill, Michael Mahmoudi

October 31, 2016

Presentation TCT 2016

Debate: Should All Low-Risk Patients With Severe Aortic Stenosis Who are Suitable Be Allowed to Choose TAVR Rather than Surgical AVR, Without Further Trial Evidence? Con Position

Presenter: Niall T. Mulvihill, Hellmuth Weich

October 31, 2016

Presentation TCT 2016

Debate: Should All Low-Risk Patients With Severe Aortic Stenosis Who are Suitable Be Allowed to Choose TAVR Rather than Surgical AVR, Without Further Trial Evidence? Pro Position

Presenter: Niall T. Mulvihill, Antoniette Neylon

October 31, 2016

Presentation TCT 2016

Introduction: TAVR in Intermediate-Risk and Low-Risk With Severe Aortic Stenosis

Presenter: Niall T. Mulvihill

October 31, 2016

Presentation TCT 2016

Editorial Perspective: Embolic Protection in TAVR Intervention

Presenter: Josep Rodés-Cabau

October 31, 2016

Presentation TCT 2016

Treatment Options After Unsuccessful Aortic Valve Replacement

Presenter: Alejandro Cherro, Oscar A. Mendiz

October 30, 2016

Presentation TCT 2016

Simultaneous TAVR and Endovascular Aortic Aneurysm Repair

Presenter: Habib Gamra, Mahmoud Hashemian, Abdullah Shehab, Walid Ouertani

October 30, 2016

Presentation TCT 2016

Management Options for Postsurgical Paravalvular Aortic Regurgitation

Presenter: Alejandro Cherro, Fernando Cura

October 30, 2016

Advertisement

Percutaneous Suture Based PFO Closure with the NobleStitch EL Device: Initial Multicenter Clinical Experience

Prospective Single Center FIH Clinical Trial to Evaluate the Safety and Effectiveness of a Septal Occluder with Bioresorbable Framework in Patients with Clinically Significant ASD or PFO

Trial #9 - The Essentials ofIN.PACT SFA: 3-year Outcomes of a Paclitaxel-Coated Balloon for Femoropopliteal Lesions

ACT I Critique: Pro and Con

Trial #8 - The Essentials ofThe ACT I Trial: Carotid Stenting vs Surgery In Asymptomatic Patients

CTSN Severe MR 2-Year Critique: Pro and Con

Trial #7 - The Essentials ofCTSN SMR Trial - Two-Year Outcomes Following Mitral Valve Repair or Replacement for Severe Ischemic Mitral Regurgitation

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

Case Resolution: How Did We Treat this Patient?

TAVR Restenosis: Review of the Literature

Case Introduction: An 87 Year Old Woman With Recurrent Dyspnea 7 Years After TAVR

TAVR for Intermediate-Risk and Low-Risk Patients: Review of the Literature

Debate: Should All Low-Risk Patients With Severe Aortic Stenosis Who are Suitable Be Allowed to Choose TAVR Rather than Surgical AVR, Without Further Trial Evidence? Con Position

Debate: Should All Low-Risk Patients With Severe Aortic Stenosis Who are Suitable Be Allowed to Choose TAVR Rather than Surgical AVR, Without Further Trial Evidence? Pro Position

Introduction: TAVR in Intermediate-Risk and Low-Risk With Severe Aortic Stenosis

Editorial Perspective: Embolic Protection in TAVR Intervention

Treatment Options After Unsuccessful Aortic Valve Replacement

Simultaneous TAVR and Endovascular Aortic Aneurysm Repair

Management Options for Postsurgical Paravalvular Aortic Regurgitation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content